ArticleInvestigative ophthalmology & visual science2026
Cumulative Loss of Inner Retinal Neurons in Healthy and Glaucoma Subjects.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Purpose: Considerable ganglion cell (GC) loss occurs over the normal human lifespan and even more in ocular diseases such as glaucoma. Current clinical methods, however, lack sufficient resolution and sensitivity to directly detect GC loss. Here, we used adaptive optics optical coherence tomography (AO-OCT) to overcome these limitations, enabling longitudinal tracking of individual GC somas and direct measurement of their loss in healthy and glaucomatous eyes. Methods: Six healthy subjects and two patients with glaucoma were imaged at multiple retinal locations using AO-OCT. Healthy subjects were imaged annually for up to 3 years (4 total timepoints); patients with glaucoma were reimaged 2 to 3 years after baseline. Individual ganglion cell layer (GCL) somas were identified and tracked across sessions and soma densities were quantified. A flicker-based image comparison approach enabled sensitive detection of soma loss from which cumulative loss was determined by subject and location. Results: The GCL soma mosaic was highly stable, with 23,586 somas tracked in healthy subjects. Soma densities agreed with histologic values, including near the fovea, and correlated strongly with GCL thickness (R2 = 0.96). The mean soma loss rate in healthy subjects was -0.10%/year (95% confidence interval [CI] = -0.09 to -0.11%/year), with no significant differences across subjects or locations. By contrast, one glaucoma patient showed a loss rate within an arcuate defect over 100× greater (-31.6%/year; corresponding GCL thinning rate of -13%/year), whereas the other demonstrated a near-normal rate (-0.26%/year). Conclusions: In vivo measurement of individual GC soma loss is now feasible and provides a sensitive tool for longitudinal evaluation of GC health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.